Monoclonal antibodies give your body ready-made protection against infectious disease — targeted, proven, and made without a live virus. Yet the rules haven't caught up with the science.
Join the movement to modernize how life-saving antibody treatments reach the people who need them.
No spam. Just clear, science-based updates. Unsubscribe anytime.
A 90-second look at what mAbs are, how they work, and why the science is already here.
When your body fights an infection, it makes antibodies — precision-guided proteins that lock onto a specific threat. Scientists can now identify the best one, copy it, and give it to you directly — so you're protected right away.
Designed to bind one specific pathogen — nothing more, nothing less.
You receive the finished antibody, so protection doesn't wait on your immune system to build it.
Made in the lab from a single antibody — not from a live or weakened pathogen.
A natural approach to immune defense — optimized by science for precision and speed.
Scientists isolate the most effective antibodies from recovered patients — or engineer them to target specific viral proteins.
These antibodies are cloned and optimized for maximum potency and duration — extending protection for months from a single dose.
Once administered, mAbs immediately bind to the pathogen, blocking it from entering cells and flagging it for immune cleanup.
No immune activation needed. Your body receives ready-made defense that works alongside your natural immune system.
When a virus mutates, a monoclonal antibody can be re-targeted to the new variant relatively quickly. But today's approval rules don't give mAbs the fast track that vaccines get.
Get an accelerated pathway to update for a new variant.
Face a longer road — even when the underlying antibody is already proven safe.
A treatment that could protect people in months can sit on the shelf for years. We're working to fix that.
A therapeutic mAb isn't a foreign substance — it's the same class of protein your own immune system produces, just identified, copied, and given to you directly.
Both are valuable. But mAbs fill critical gaps that vaccines alone can't address — which is exactly why the approval rules should let them keep pace.
Vaccines and natural infection take weeks to build protection. A monoclonal antibody bridges that gap — delivering defense from day one.
Real, approved monoclonal antibodies are protecting people from infectious disease right now.
A single-dose antibody is used to help protect newborns and infants through their first RSV season.
Clinical trials published in the New England Journal of Medicine showed a single antibody dose protecting adults across a malaria season.
Antibody therapy is used to reduce recurrence of serious bacterial infections in vulnerable patients.
The more people who understand what monoclonal antibodies are, the harder it is to keep them stuck behind outdated rules. Add your name.